Larimar Therapeutics Sets June 2026 BLA Target for Nomlabofusp, Q2 Topline Data Expected
Summary
The news from Larimar Therapeutics provides crucial updates on its lead drug, nomlabofusp, including a target BLA submission in June 2026 for accelerated approval and anticipated Q2 2026 topline open-label data. This follows the recent FDA Breakthrough Therapy Designation announced in late February. The company also confirmed FDA alignment on key regulatory aspects, such as skin FXN as a potential surrogate endpoint. Additionally, the updated corporate presentation details a pro forma cash runway into Q2 2027, which is important context following the recent $100 million public offering. These specific timelines and regulatory clarity are significant catalysts for the stock, offering a clear roadmap for the drug's development and potential market entry.
At the time of this announcement, LRMR was trading at $5.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $487M. The 52-week trading range was $1.61 to $6.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.